Presently, anti-tumour drugs have already been demonstrated to target the VEGF pathway, and among these drugs, bevacizumab has been widely used clinically for the treatment of multiple cancers, particularly NSCLC [22]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.